Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Metolazone

Preparation Calculator

USE IF: Refractory congestion / diuretic resistance (often with loop diuretic), edema in HF or renal/nephrotic states, selected HTN β€” with explicit electrolyte and volume monitoring.

AVOID IF: Anuria; uncorrected severe electrolyte depletion; need for minutes-level rescue of pulmonary edema without appropriate acute loop / respiratory care.

Metolazone

Thiazide-like diuretic (distal tubule)

AdultDiureticHFRenalHTNCardiologyHigh-yieldWardInpatient

Indication

HF / renal edema β€’ Diuretic resistance (+ loop) β€’ HTN (selected)

At a glance

INDICATIONS (CORE USE)

- Edema in heart failure - Edema in renal disease / nephrotic states - Resistant edema / diuretic resistance (with loop diuretic strategy) - Hypertension (selected)

ADULT DOSE (STANDARD)

Typical start 2.5–5 mg PO daily; titrate cautiously on response + labs Often combined with a loop diuretic β€” some protocols time metolazone before the loop; monitor K, Na, Cr early

MAX DOSE

Indication- and context-dependent; higher doses increase electrolyte risk more than incremental benefit β€” avoid fixed escalation without labs

Route

PO

PEDIATRIC DOSE

Specialist / protocol-based only

Do not miss

Must-not-miss safety points

Major warning

- Severe hypokalemia / hyponatremia β†’ arrhythmia and neurologic risk - Over-diuresis β†’ AKI, hypotension - With loop diuretics: powerful diuresis, highest K/Na/renal risk (sequential nephron blockade) - Do not repeat or escalate blindly without labs and volume reassessment - Not a stand-alone rescue for acute pulmonary edema

Indications

Primary

  • Edema in heart failure
  • Edema in renal disease / nephrotic states
  • Resistant edema / diuretic resistance (with loop diuretic strategy)

Secondary

  • Hypertension (selected use)

Dosing

STANDARD (ADULT PO)

Typical starting dose 2.5–5 mg PO daily (edema / resistance: cautious titration)

ADULT DOSE

PO only. Refractory congestion: often given with a loop diuretic; common practice is metolazone before loop in selected protocols β€” unit-specific. Dose changes guided by UOP, weight, symptoms, and labs β€” not by calendar alone.

PEDIATRIC DOSE

Specialist / protocol-based only

MAX DOSE

Keep indication-dependent; avoid oversimplified fixed max β€” escalating dose raises electrolyte risk sharply

Practical Note

- + Loop: sequential nephron blockade is effective but can drop K/Na and Cr within hours to a day β€” recheck labs per risk - Do not continue blindly: if no clear benefit, reassess adherence, loop delivery, and alternative drivers of congestion - Not substitute for IV loop in acute pulmonary edema rescue

Warnings

Clinical warnings

  • Hypokalemia, hyponatremia, hypomagnesemia β€” arrhythmia risk (digoxin interaction)
  • Hypotension, dehydration, orthostasis, falls (elderly)
  • AKI from over-diuresis / prerenal pattern
  • Hyperuricemia / gout
  • Aggressive sequential nephron blockade (loop + metolazone) can destabilize K, Na, and renal function quickly
  • Thiazide-class metabolic effects (e.g. glucose) β€” monitor in diabetes

Contraindications

  • Anuria
  • Severe electrolyte depletion (uncorrected)
  • Known hypersensitivity (product labeling)

Drug interactions

  • Loop diuretics β€” synergistic diuresis; profound K/Mg/Na depletion and AKI risk
  • Digoxin β€” toxicity / arrhythmia via hypokalemia / hypomagnesemia
  • Lithium β€” reduced excretion, lithium toxicity risk
  • NSAIDs β€” reduced diuretic effect, renal risk
  • RAAS blockers, other K-wasters β€” additive electrolyte and renal effects (lab-guided)

Special populations

Pediatrics

Specialist / protocol-based only

Pregnancy

Pregnancy /

Lactation

use only if benefit exceeds risk per specialist and current labeling

Renal impairment

Used in renal edema and resistance strategies but needs close monitoring β€” high AKI and solute (Na, K) shift risk; smaller steps, more frequent labs

Hepatic impairment

Hyponatremia / HRS context β€” use only with specialist judgment and tight Na monitoring if considered

Elderly

Higher risk of hypotension, hyponatremia, falls, AKI β€” conservative dosing, early lab follow-up

Administration

- PO dosing only - In sequential nephron blockade, timing (e.g. before loop) per protocol - Do not use casually without a lab and volume follow-up plan

Monitoring

  • Monitor: volume (weight, I/O, symptoms, JVP/edema), electrolytes (Na, K, Mg), renal function (Cr/eGFR trend)
  • Recheck: very early after initiation or dose change when combined with loop diuretic; daily or more often if inpatient / high-risk; do not continue blindly if labs worsen or no net benefit
  • Hold if: severe hypokalemia, significant hyponatremia, symptomatic hypotension, AKI / rising creatinine from over-diuresis

Overdose / toxicity

Clinical Picture

Dehydration Hypotension Electrolyte derangement (K, Na, Mg) AKI / arrhythmia

Immediate Actions

Stop drug; supportive care; re-evaluate volume state and concomitant loop dose

Antidote

None specific β€” correct fluids and electrolytes per presentation (avoid rapid overcorrection of chronic hyponatremia)

Decontamination

Acute large ingestion: poison center; supportive care mainstay

Escalation

Shock, life-threatening K or arrhythmia, refractory AKI β€” escalate per ED/ICU/nephrology

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • High value in diuretic resistance, especially with loop diuretics
  • Primary danger: over-diuresis and electrolyte collapse without lab follow-up

Clinical

  • Sequential nephron blockade works; K/Na/Cr can shift faster than with loop alone
  • Common error: repeating or escalating without checking response and labs

Safety

  • Not a minutes-level rescue for acute pulmonary edema β€” acute care is loop-directed plus supportive care
  • With loop: plan early electrolyte recheck, not ad hoc

Pharmacy Tool

Preparation Calculator

Metolazone 1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Oral only - Long duration of effect; natriuretic and electrolyte effects can outlast the dose interval in sensitive patients

Mechanism of action

- Thiazide-like inhibition of distal nephron sodium/chloride reabsorption - Different segment from loop diuretics β€” allows sequential nephron blockade when co-prescribed (with added electrolyte risk)

Common brand names

Saudi Arabia

Zaroxolyn, Metolazone

Global

Mykrox, (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC/AHA and HFSA heart failure guidance (decongestion, diuretic resistance)
  • KDIGO / CKD management references where applicable
  • Product labeling (FDA, SFDA, EMA) for metolazone